60 DEGREES PHARMACEUTICALS, INC. 8-K

What Happened

• 60 Degrees Pharmaceuticals, Inc. (SXTP) filed an 8-K on March 12, 2026 announcing an updated legal opinion of counsel related to shares issued and sold under its "at‑the‑market" (ATM) equity offering program.
• The updated opinion, attached as Exhibit 5.1, relates to the Sales Agreement dated September 5, 2025 between the Company and HC Wainwright & Co., LLC, and confirms the validity of shares that may be sold under the ATM and certain legal matters governing those offerings.

Key Details

• Filing date: March 12, 2026.
• Sales Agreement counterparty: HC Wainwright & Co., LLC (agreement dated September 5, 2025).
• Counsel providing the opinion: Sichenzia Ross Ference Carmel LLP (opinion filed as Exhibit 5.1; consent included).
• The opinion does not change the terms of the ATM program; it provides legal confirmation regarding the validity of shares and related offering matters under applicable law.

Why It Matters

• For investors, the updated legal opinion reduces legal uncertainty by confirming the shares sold under the ATM are validly issued, which supports the Company's ability to raise capital through the ATM program.
• This is a legal/administrative update—not a new financing or change in program terms—so it does not by itself alter the number of shares outstanding or the mechanics of the offering.